BioMarin Pharmaceutical traded at $55.50 this Thursday April 2nd, decreasing $1.74 or 3.04 percent since the previous trading session. Looking back, over the last four weeks, BioMarin Pharmaceutical lost 5.18 percent. Over the last 12 months, its price fell by 17.75 percent. Looking ahead, we forecast BioMarin Pharmaceutical to be priced at 53.83 by the end of this quarter and at 49.11 in one year, according to Trading Economics global macro models projections and analysts expectations.
BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.